- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote
- Sector Info (pharmaceuticals)
- Indian Pharma
Indian Pharma Stocks 
Here are the latest stock price details of India's top Indian Pharma stocks. For more detailed updates, read our Indian Pharma sector report and check the latest Indian Pharma sector results.
| SCRIP | BSE PRICE (Rs) | NSE PRICE (Rs) | CHART | MORE INFO |
|---|---|---|---|---|
| AARTI DRUGS | 573.15 -0.11% | 573.35 -0.52% | More Info
|
|
| AJANTA PHARMA | 1,005.55 0.44% | 1,002.35 0.12% | More Info
|
|
| ALEMBIC PHARMA | 608.10 0.81% | 607.95 0.19% | More Info
|
|
| BIOCON LTD | 658.45 3.47% | 661.05 3.85% | More Info
|
|
| CADILA HEALTHCARE | 372.00 -1.40% | 371.75 -1.54% | More Info
|
|
| CIPLA | 633.85 -0.98% | 633.80 -1.04% | More Info
|
|
| DIVIS LABORATORIES | 1,288.75 -0.85% | 1,285.25 -1.23% | More Info
|
|
| GLENMARK PHARMA | 599.50 -0.08% | 599.00 -0.12% | More Info
|
|
| INDOCO REMEDIES | 187.30 -1.50% | 187.95 -1.10% | More Info
|
|
| IPCA LABS | 667.80 -0.38% | 668.35 -0.52% | More Info
|
|
| J.B.CHEMICALS | 304.05 1.74% | 304.50 1.45% | More Info
|
|
| LUPIN LTD | 877.60 -1.99% | 880.25 -1.83% | More Info
|
|
| NATCO PHARMA | 726.55 0.85% | 726.75 1.30% | More Info
|
|
| NIFTY 50 | Not Listed | 10,303.55 -1.43% | More Info
|
|
| ORCHID PHARMA LTD | 5.67 -1.05% | 18.90 -2.83% | More Info
|
|
| PANACEA BIOTECH | 161.90 -4.26% | 160.80 -2.84% | More Info
|
|
| PIRAMAL ENTERPRISES | 1,894.70 -9.73% | 1,893.95 -9.76% | More Info
|
|
| S&P BSE SENSEX | 34,315.63 -1.33% | Not Listed | More Info
|
|
| STRIDES SHASUN LTD | 424.35 -2.10% | 423.60 -2.33% | More Info
|
|
| SUN PHARMA | 608.40 2.52% | 609.95 2.78% | More Info
|
|
| TORRENT PHARMA | 1,563.35 0.23% | 1,562.80 0.12% | More Info
|
|
| WOCKHARDT LTD. | 481.35 -2.04% | 480.70 -1.97% | More Info
|
BSE prices: October 19, 2018 (Close) NSE prices: October 19, 2018 (Close)
Indian Pharma Stocks Update
The NIFTY PHARMA Index was at 9,637.8 (down 0.5%). The index is down 6.5% over the last 30 days. And over the last 1 year, it has gained 2.6%.
Within the Indian Pharma sector, the top gainers were BIOCON LTD (up 3.5%) and SUN PHARMA (up 2.5%). On the other hand, PIRAMAL ENTERPRISES (down 9.7%) and PANACEA BIOTECH (down 4.3%) were among the top losers.
Meanwhile, the benchmark NIFTY 50 was at 10,303.6 (down 1.4%).
|
| |
Today's Market
Sensex Ends Over 450 Points Lower; IT and Energy Stocks Witness Selling(Closing)
Share markets in India continued their sell-off seen during the day and ended the trading session deep in the red. All sectoral indices traded on a negative note with stocks in the IT sector.
Related Views on News
MAGMA FINCORP Plunges by 5%; BSE 500 Index Down 1.5% (Market Updates)
Oct 19, 2018 | Updated on Oct 19, 2018MAGMA FINCORP share price has plunged by 5% and its current market price is Rs 103. The BSE 500 is down by 1.5%. The top gainers in the BSE 500 Index are LAKSHMI VILAS BANK (up 7.7%) and JET AIRWAYS (up 5.9%). The top losers are MAGMA FINCORP (down 5.1%) and PIRAMAL ENTERPRISES (down 9.7%).
MUTHOOT FINANCE Plunges by 5%; BSE 500 Index Down 1.4% (Market Updates)
Oct 19, 2018 | Updated on Oct 19, 2018MUTHOOT FINANCE share price has plunged by 5% and its current market price is Rs 404. The BSE 500 is down by 1.4%. The top gainers in the BSE 500 Index are LAKSHMI VILAS BANK (up 7.3%) and JET AIRWAYS (up 6.5%). The top losers are MUTHOOT FINANCE (down 5.2%) and PIRAMAL ENTERPRISES (down 9.8%).
HEIDELBERG CEMENT Plunges by 5%; BSE 500 Index Down 1.3% (Market Updates)
Oct 19, 2018 | Updated on Oct 19, 2018HEIDELBERG CEMENT share price has plunged by 5% and its current market price is Rs 144. The BSE 500 is down by 1.3%. The top gainers in the BSE 500 Index are LAKSHMI VILAS BANK (up 7.4%) and RELIANCE INFRA (up 6.7%). The top losers are HEIDELBERG CEMENT (down 5.3%) and PIRAMAL ENTERPRISES (down 9.3%).
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
More Views on NewsMost Popular
This Market Crash could be the Biggest Wealth Creating Opportunity Since 2008(Profit Hunter)
Oct 8, 2018While widespread fear is the friend of a value investor, serving up bargain purchases; personal fear is an investor's biggest enemy.
My Top 3 Tips to Navigate the Market Crash(The 5 Minute Wrapup)
Oct 8, 2018Steep corrections are never easy to handle. It's hard to watch the value of your shares drop so much. But you can take steps to make the most of it.
IPO Market Feels the Heat of the Market Crash(Sector Info)
Oct 12, 2018The sentiments in primary market have also deteriorated amid the stock market correction. Most listed IPOs of 2018 are trading below their issue price.
Even If IL&FS Group Brought This Correction, this is Right Time to Buy & Sit Tight!(Chart Of The Day)
Oct 12, 2018Even if IL&FS is the culprit, it may turn out to be a hero if you buy right and sit tight.
ICICI Prudential Manufacture In India Fund: A Make In India Prodigy, Should You Invest?(Outside View)
Oct 8, 2018PersonalFN briefly explains if you should be investing in the NFO: ICICI Prudenetial Manufacture in India Fund.
More|
| |
S&P BSE HEALTHCARE
Oct 19, 2018 (Close)
S&P BSE HEALTHCARE 5-YR ANALYSIS
COMPARE COMPANY
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.